CAR T-cell therapy has impressive anti-tumor activity in a variety of hematologic cancers including pediatric acute lymphoblastic leukemia (ALL), diffuse large B-cell non-Hodgkin’s lymphoma (NHL), mantle cell NHL, multiple myeloma, and chronic lymphocytic leukemia (CLL), leading to the commercial approval of four CD19-directed CAR T-cell products. While CAR T-cells are promising treatments for relapsed/refractory hematologic cancers, they are limited by two significant toxicities, CRS and ICANS. Proven management options for CRS and ICANS are limited to tocilizumab and corticosteroids.